Laura Obici

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1181845/publications.pdf

Version: 2024-02-01

182	14,117	18482 62	21540 114
papers	citations	h-index	g-index

192	192	192	8537
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. New England Journal of Medicine, 2018, 379, 22-31.	27.0	1,000
2	Systemic Cardiac Amyloidoses. Circulation, 2009, 120, 1203-1212.	1.6	622
3	Repurposing Diflunisal for Familial Amyloid Polyneuropathy. JAMA - Journal of the American Medical Association, 2013, 310, 2658.	7.4	551
4	Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet Journal of Rare Diseases, 2013, 8, 31.	2.7	525
5	Serum N-Terminal Proâ€“Brain Natriuretic Peptide Is a Sensitive Marker of Myocardial Dysfunction in AL Amyloidosis. Circulation, 2003, 107, 2440-2445.	1.6	456
6	Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood, 2004, 103, 2936-2938.	1.4	375
7	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Annals of the Rheumatic Diseases, 2013, 72, 678-685.	0.9	350
8	Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. New England Journal of Medicine, 2018, 378, 1908-1919.	27.0	327
9	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
10	Persistent efficacy of anakinra in patients with tumor necrosis factor receptorâ€“associated periodic syndrome. Arthritis and Rheumatism, 2008, 58, 1516-1520.	6.7	297
11	Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood, 2006, 107, 3854-3858.	1.4	266
12	The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Annals of the Rheumatic Diseases, 2014, 73, 2160-2167.	0.9	256
13	Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. European Heart Journal, 2013, 34, 520-528.	2.2	252
14	Eprodisate for the Treatment of Renal Disease in AA Amyloidosis. New England Journal of Medicine, 2007, 356, 2349-2360.	27.0	240
15	Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine. Clinical Chemistry, 2009, 55, 499-504.	3.2	225
16	Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature Recommendations. Human Mutation, 2014, 35, E2403-E2412.	2.5	220
17	Clinical aspects of systemic amyloid diseases. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2005, 1753, 11-22.	2.3	215
18	The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood, 2005, 105, 2949-2951.	1.4	207

#	Article	IF	Citations
19	â€œRedâ€flagâ€•symptom clusters in transthyretin familial amyloid polyneuropathy. Journal of the Peripheral Nervous System, 2016, 21, 5-9.	3.1	201
20	Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC: Heart Failure, 2019, 7, 709-716.	4.1	188
21	The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood, 2010, 116, 3426-3430.	1.4	184
22	Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 34-36.	3.0	184
23	Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood, 2007, 110, 787-788.	1.4	182
24	First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Current Opinion in Neurology, 2016, 29, S14-S26.	3.6	179
25	Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe. Current Opinion in Neurology, 2016, 29, S3-S13.	3.6	173
26	Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis. Neurodegenerative Disease Management, 2019, 9, 5-23.	2.2	168
27	A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis and Rheumatism, 2008, 58, 1823-1832.	6.7	165
28	Guidelines for the genetic diagnosis of hereditary recurrent fevers. Annals of the Rheumatic Diseases, 2012, 71, 1599-1605.	0.9	160
29	A practical approach to the diagnosis of systemic amyloidoses. Blood, 2015, 125, 2239-2244.	1.4	156
30	Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood, 2012, 119, 1844-1847.	1.4	155
31	Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2002, 9, 108-114.	3.0	141
32	Neutrophils from patients withTNFRSF1A mutations display resistance to tumor necrosis factorâ€“induced apoptosis: Pathogenetic and clinical implications. Arthritis and Rheumatism, 2006, 54, 998-1008.	6.7	138
33	Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica, 2014, 99, 743-750.	3.5	138
34	Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2006, 13, 191-205.	3.0	124
35	Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin Amyloidosis. Journal of Cardiovascular Translational Research, 2013, 6, 1011-1020.	2.4	122
36	Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched caseâ€“control study on 174 patients. Leukemia, 2014, 28, 2311-2316.	7.2	113

#	Article	IF	Citations
37	Rapid progression of familial amyloidotic polyneuropathy. Neurology, 2015, 85, 675-682.	1.1	109
38	The New Apolipoprotein A-I Variant Leu174 â†' Ser Causes Hereditary Cardiac Amyloidosis, and the Amyloid Fibrils Are Constituted by the 93-Residue N-Terminal Polypeptide. American Journal of Pathology, 1999, 155, 695-702.	3.8	108
39	Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 142-150.	3.0	106
40	Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. Arthritis and Rheumatism, 2009, 61, 1435-1440.	6.7	100
41	The repertoire of Î» light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood, 2012, 119, 144-150.	1.4	98
42	Amyloidosis in autoinflammatory syndromes. Autoimmunity Reviews, 2012, 12, 14-17.	5.8	96
43	Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Annals of the Rheumatic Diseases, 2017, 76, 173-178.	0.9	96
44	Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. American Journal of Hematology, 2012, 87, 465-471.	4.1	95
45	Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurology, The, 2021, 20, 49-59.	10.2	93
46	AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Medical Weekly, 2012, 142, w13580.	1.6	87
47	Conformational Switching and Fibrillogenesis in the Amyloidogenic Fragment of Apolipoprotein A-I. Journal of Biological Chemistry, 2003, 278, 2444-2451.	3.4	86
48	Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Annals of the Rheumatic Diseases, 2011, 70, 1511-1512.	0.9	86
49	Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. Current Opinion in Neurology, 2016, 29, S27-S35.	3.6	86
50	Renal Apolipoprotein A-I Amyloidosis: A Rare and Usually Ignored Cause of Hereditary Tubulointerstitial Nephritis. Journal of the American Society of Nephrology: JASN, 2005, 16, 3680-3686.	6.1	83
51	Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 457-458.	1.9	83
52	A novelAÎ²PP mutation exclusively associated with cerebral amyloid angiopathy. Annals of Neurology, 2005, 58, 639-644.	5.3	81
53	First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis and Rheumatism, 2004, 50, 2966-2969.	6.7	79
54	Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide. Annals of Hematology, 2012, 91, 89-92.	1.8	78

#	Article	IF	Citations
55	Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area. Journal of Neurology, 2016, 263, 916-924.	3.6	76
56	MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever. European Journal of Human Genetics, 2005, 13, 314-320.	2.8	71
57	The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: Clinical manifestations and long-term follow-up. Seminars in Arthritis and Rheumatism, 2014, 43, 818-823.	3.4	71
58	Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families. Gastroenterology, 2004, 126, 1416-1422.	1.3	70
59	Variable presentations of TTRâ€related familial amyloid polyneuropathy in seventeen patients. Journal of the Peripheral Nervous System, 2011, 16, 119-129.	3.1	68
60	Plasminogen activation triggers transthyretin amyloidogenesis in vitro. Journal of Biological Chemistry, 2018, 293, 14192-14199.	3.4	68
61	A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. British Journal of Haematology, 2001, 113, 1044-1046.	2.5	67
62	Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Annals of Hematology, 2009, 88, 347-350.	1.8	67
63	The workings of the amyloid diseases. Annals of Medicine, 2007, 39, 200-207.	3.8	62
64	The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 80-82.	3.0	59
65	Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases. Annals of the Rheumatic Diseases, 2016, 75, 1550-1557.	0.9	57
66	Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. European Journal of Heart Failure, 2021, 23, 895-905.	7.1	57
67	Evidence That Amyloidogenic Light Chains Undergo Antigen-Driven Selection. Blood, 1998, 91, 2948-2954.	1.4	56
68	Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 143-155.	3.0	55
69	ATTRv amyloidosis Italian Registry: clinical and epidemiological data. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 259-265.	3.0	51
70	Validation of a Diagnostic Score for the Diagnosis of Autoinflammatory Diseases in Adults. International Journal of Immunopathology and Pharmacology, 2011, 24, 695-702.	2.1	50
71	Early data on longâ€term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2â€year update from the openâ€label extension of the NEUROâ€TTR trial. European Journal of Neurology, 2020, 27, 1374-1381.	3.3	49
72	Effects of the Known Pathogenic Mutations on the Aggregation Pathway of the Amyloidogenic Peptide of Apolipoprotein A-I. Journal of Molecular Biology, 2011, 407, 465-476.	4.2	48

#	Article	IF	Citations
73	An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis. Expert Opinion on Investigational Drugs, 2014, 23, 1239-1251.	4.1	47
74	Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 153-162.	3.0	47
75	A Narrative Review of the Role of Transthyretin in Health and Disease. Neurology and Therapy, 2020, 9, 395-402.	3.2	47
76	Therapeutic advances demand accurate typing of amyloid deposits. American Journal of Medicine, 2001, 111, 243-244.	1.5	46
77	AL Amyloidosis Associated with IgM Monoclonal Protein: A Distinct Clinical Entity. Clinical Lymphoma and Myeloma, 2009, 9, 80-83.	1.4	45
78	Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. Protein Science, 2001, 10, 187-199.	7.6	44
79	First Report of Circulating MicroRNAs in Tumour Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS). PLoS ONE, 2013, 8, e73443.	2.5	44
80	TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurological Sciences, 2013, 34, 1057-1063.	1.9	43
81	The novel S59P mutation in the TNFRSF1A gene identified in an adult onset TNF receptor associated periodic syndrome (TRAPS) constitutively activates NF-ÎºB pathway. Arthritis Research and Therapy, 2015, 17, 93.	3.5	43
82	Treatment of AL Amyloidosis with 4â€²-Iodo-4â€²-Deoxydoxorubicin: An Update. Blood, 1999, 93, 1112-1113.	1.4	41
83	Assessment of patients with hereditary transthyretin amyloidosis â€“ understanding the impact of management and disease progression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 103-111.	3.0	40
84	The Diflunisal Trial: Study accrual and drug tolerance. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 37-38.	3.0	39
85	Burden of hereditary transthyretin amyloidosis on quality of life. Muscle and Nerve, 2019, 60, 169-175.	2.2	39
86	Understanding the Pathophysiology of Cerebral Amyloid Angiopathy. International Journal of Molecular Sciences, 2020, 21, 3435.	4.1	39
87	Nerve ultrasound in hereditary transthyretin amyloidosis: red flags and possible progression biomarkers. Journal of Neurology, 2021, 268, 189-198.	3.6	38
88	Treatment of IgM-Associated AL Amyloidosis With the Combination of Rituximab, Bortezomib, and Dexamethasone. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 143-145.	0.4	36
89	Next generation sequencing panel in undifferentiated autoinflammatory diseases identifies patients with colchicine-responder recurrent fevers. Rheumatology, 2020, 59, 344-360.	1.9	36
90	Clinical Pregenetic Screening for Stroke Monogenic Diseases. Stroke, 2016, 47, 1702-1709.	2.0	34

#	Article	IF	Citations
91	Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurology and Therapy, 2021, 10, 375-389.	3.2	34
92	Ocular Involvement in Hereditary Amyloidosis. Genes, 2021, 12, 955.	2.4	33
93	Clinical Characteristics of Patients Carrying the Q703K Variant of the NLRP3 Gene: A 10-year Multicentric National Study. Journal of Rheumatology, 2016, 43, 1093-1100.	2.0	31
94	Plasma neurofilament light chain: an early biomarker for hereditary ATTR amyloid polyneuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 97-102.	3.0	31
95	Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Annals of the Rheumatic Diseases, 2017, 76, 303-309.	0.9	30
96	Protein Aggregation. Clinical Chemistry and Laboratory Medicine, 2001, 39, 1065-75.	2.3	29
97	Tubulointerstitial nephritis is a dominant feature of hereditary apolipoprotein A-I amyloidosis. Kidney International, 2015, 87, 1223-1229.	5.2	28
98	Cryopyrin-associated Periodic Syndromes in Italian Patients: Evaluation of the Rate of Somatic NLRP3 Mosaicism and Phenotypic Characterization. Journal of Rheumatology, 2017, 44, 1667-1673.	2.0	28
99	Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 216-221.	3.0	26
100	Transthyretin deposition in the eye in the era of effective therapy for hereditary ATTRV30M amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 10-14.	3.0	26
101	Amyloidosis in Heart Failure. Current Heart Failure Reports, 2019, 16, 285-303.	3.3	26
102	Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis. Expert Review of Clinical Pharmacology, 2019, 12, 701-711.	3.1	25
103	Infertility and Hypergonadotropic Hypogonadism as First Evidence of Hereditary Apolipoprotein A-I Amyloidosis. Journal of Urology, 2007, 178, 344-348.	0.4	24
104	Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 173-178.	3.0	24
105	Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-Î± Receptorâ€"Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-12.	3.0	24
106	Expression, regulation and localisation of dystrophin isoforms in human foetal skeletal and cardiac muscle. Neuromuscular Disorders, 1999, 9, 541-551.	0.6	23
107	The intracellular quality control system down-regulates the secretion of amyloidogenic apolipoprotein A-I variants: A possible impact on the natural history of the disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 87-93.	3.8	22
108	Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 92-93.	3.0	21

#	Article	IF	Citations
109	Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy. Muscle and Nerve, 2016, 54, 353-360.	2.2	21
110	Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis. Clinical Autonomic Research, 2019, 29, 55-63.	2.5	21
111	The diflunisal trial: update on study drug tolerance and disease progression. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 196-197.	3.0	20
112	Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis. Journal of Neurology, 2020, 267, 1070-1079.	3.6	20
113	Hereditary Amyloidosis. New England Journal of Medicine, 2002, 347, 1206-1207.	27.0	19
114	Description of a large cohort of Caucasian patients with <scp>V122I ATTRv</scp> amyloidosis: Neurological and cardiological features. Journal of the Peripheral Nervous System, 2020, 25, 273-278.	3.1	18
115	Mass spectrometry-based proteomics as a diagnostic tool when immunoelectron microscopy fails in typing amyloid deposits. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 64-66.	3.0	17
116	Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations. Clinica Chimica Acta, 2011, 412, 1262-1265.	1.1	17
117	Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene. Journal of Rheumatology, 2011, 38, 1378-1384.	2.0	17
118	High^{99m}Tc-DPD myocardial uptake in a patient with apolipoprotein AI-related amyloidotic cardiomyopathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 48-51.	3.0	16
119	Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system. Journal of Neuroinflammation, 2017, 14, 115.	7.2	16
120	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptorâ€“associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. Journal of Rheumatology, 2019, 46, 429-436.	2.0	16
121	INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 783-791.e4.	3.8	16
122	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13598.	3.4	16
123	Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome. Journal of Leukocyte Biology, 2016, 99, 761-769.	3.3	15
124	A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors. Journal of Allergy and Clinical Immunology, 2020, 145, 368-378.e13.	2.9	14
125	Age-related amyloidosis outside the brain: A state-of-the-art review. Ageing Research Reviews, 2021, 70, 101388.	10.9	14
126	Atypical familial motor neuropathy in patients with mutant TTR Ile68Leu. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2003, 10, 185-189.	3.0	13

#	Article	IF	Citations
127	Progressive brachial plexus enlargement in hereditary transthyretin amyloidosis. Journal of Neurology, 2022, 269, 1905-1912.	3.6	13
128	Realâ€life experience with inotersen in hereditary transthyretin amyloidosis with lateâ€onset phenotype: Data from an earlyâ€access program in Italy. European Journal of Neurology, 2022, 29, 2148-2155.	3.3	13
129	Acquired and inherited amyloidosis: Knowledge driving patients' care. Journal of the Peripheral Nervous System, 2020, 25, 85-101.	3.1	12
130	Mutation and transcription analysis of transthyretin gene in Italian families with hereditary amyloidosis: a putative novel â€˜hot spotâ€™ in codon 47. Clinical Genetics, 2001, 57, 284-290.	2.0	11
131	Amyloid Formation by Globular Proteins: The Need to Narrow the Gap Between in Vitro and in Vivo Mechanisms. Frontiers in Molecular Biosciences, 2022, 9, 830006.	3.5	11
132	Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene. Annals of the Rheumatic Diseases, 2014, 73, 290-297.	0.9	10
133	Expanding the spectrum of systemic amyloid diseases: aÂnew hint from the kidney. Kidney International, 2016, 90, 479-481.	5.2	10
134	Prognostication of survival and progression to dialysis in AA amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 136-137.	3.0	9
135	An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis. Expert Opinion on Pharmacotherapy, 2019, 20, 2223-2228.	1.8	9
136	Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR. Neurology and Therapy, 2021, 10, 865-886.	3.2	9
137	Late-Onset Familial Mediterranean Fever: An Atypical Presentation of Dermatologic Interest. Archives of Dermatology, 2007, 143, 1073.	1.4	8
138	Proteomics in protein misfolding diseases. Clinical Chemistry and Laboratory Medicine, 2009, 47, 627-35.	2.3	8
139	Changes in tissue proteome associated with ATTR amyloidosis: insights into pathogenesis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 11-13.	3.0	8
140	Preliminary assessment of neuropathy progression in patients with hereditary ATTR amyloidosis after orthotopic liver transplantation (OLT). Orphanet Journal of Rare Diseases, 2015, 10, P19.	2.7	8
141	Psychosocial burden and professional and social support in patients with hereditary transthyretin amyloidosis (ATTRv) and their relatives in Italy. Orphanet Journal of Rare Diseases, 2021, 16, 163.	2.7	8
142	Current and Emerging Therapies for Hereditary Transthyretin Amyloidosis: Strides Towards a Brighter Future. Neurotherapeutics, 2021, 18, 2286-2302.	4.4	8
143	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. Mediators of Inflammation, 2020, 2020, 1-6.	3.0	7
144	Structure dynamics of ApoA-I amyloidogenic variants in small HDL increase their ability to mediate cholesterol efflux. Journal of Lipid Research, 2021, 62, 100004.	4.2	7

#	Article	IF	Citations
145	Role of NT-ProBNP to Assess the Adequacy of Treatment Response in AL Amyloidosis.. Blood, 2008, 112, 1689-1689.	1.4	7
146	The impact of the Eurofever criteria and the new InFevers MEFV classification in real life: Results from a large international FMF cohort. Seminars in Arthritis and Rheumatism, 2022, 52, 151957.	3.4	7
147	Etiology of Amyloidosis Determines Myocardial 99mTc-DPD Uptake in Amyloidotic Cardiomyopathy. Clinical Nuclear Medicine, 2015, 40, 446-447.	1.3	6
148	Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndromeâ€"Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network. Frontiers in Medicine, 2021, 8, 668173.	2.6	6
149	Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2009, 16, 115-121.	3.0	5
150	Proteomic characterization of amyloid deposits in transthyretin amyloidosis associated with various mutations. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 61-63.	3.0	5
151	Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: prospective study in 206 patients. Blood, 2019, 134, 320-323.	1.4	5
152	Treatment of AL Amyloidosis with Bortezomib Combined with Alkylating Agents: Results From a Prospective Series of Unselected Patients,. Blood, 2011, 118, 3977-3977.	1.4	5
153	Report from the Diagnostic Interactive Session. , 2007, , 377-382.		5
154	Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2011, 18, 96-97.	3.0	4
155	THU0396â€...Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome (TRAPS). Annals of the Rheumatic Diseases, 2013, 71, 289.2-289.	0.9	4
156	Vascular alterations in apolipoprotein A-I amyloidosis (Leu75Pro). A caseâ€"control study. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2015, 22, 187-193.	3.0	4
157	Persistence of disease flares is associated with an inadequate colchicine dose in familial Mediterranean fever: A national multicenter longitudinal study. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3218-3220.e1.	3.8	4
158	HELIOS-A: 9-month results from the phase 3 study of vutrisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Journal of the Neurological Sciences, 2021, 429, 117767.	0.6	4
159	FRI0568â€...THE USE OF NEXT GENERATION SEQUENCING PANEL IN UNDIFFERENTIATED AUTOINFLAMMATORY DISEASES IDENTIFY A SEPARATE SUBSET OF COLCHICINE-RESPONDER RECURRENT FEVERS DISTINCT FROM PFAPA SYNDROME. , 2019, , .		3
160	Discovering the Italian phenotype of cerebral amyloid angiopathy (CAA): the SENECA project. Neurological Sciences, 2020, 41, 2193-2200.	1.9	3
161	AA amyloidosis in inflammatory active malignant paraganglioma. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 137-138.	3.0	3
162	Hereditary apolipoprotein A1 amyloidosis with cutaneous and cardiac involvement: a long familial history. European Journal of Dermatology, 2014, 24, 261-263.	0.6	2

#	Article	IF	Citations
163	Seek and You Shall Find: Is Subclinical Amyloid More Common Than Expected?. Mayo Clinic Proceedings, 2018, 93, 1546-1548.	3.0	2
164	Amyloid Typing: Immunoelectron Microscopy. , 2012, , 249-260.		2
165	THU0376â€...Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Annals of the Rheumatic Diseases, 2013, 71, 282.3-283.	0.9	1
166	Progressive axonal polyneuropathy in a mitochondrial disorder: an uncommon association with familial amyloid neuropathy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 261-262.	3.0	1
167	Becoming familiar with hereditary transthyretin amyloidosis, a treatable neuropathy. Arquivos De Neuro-Psiquiatria, 2018, 76, 573-574.	0.8	1
168	OP0107â€...Clinical features at presentation in a series of 86 patients with genetically confirmed traps and 33 patients with inflammatory symptoms and the r92q variant from the eurofevers/eurotraps registry:. Annals of the Rheumatic Diseases, 2013, 71, 89.2-89.	0.9	0
169	THU0482â€...Gene Expression Profiling of Whole Blood Samples of TRAPS Patients Shows Insight into the Molecular Pathogenesis of TRAPS and Response to Canakinumab Treatment. Annals of the Rheumatic Diseases, 2014, 73, 349.4-350.	0.9	0
170	THU0539â€...Clinical Presentation of Cryopyrin-Associated Periodic Syndrome (CAPS) in Carriers of the Q703K Mutation in the CIAS1/NLRP3 Gene: Genotype-Phenotype Characterization of a Family. Annals of the Rheumatic Diseases, 2015, 74, 395.2-395.	0.9	0
171	SAT0532â€...Efficacy and Safety of Canakinumab in Patients with Active Recurrent or Chronic TNF-Receptor Associated Periodic Syndrome (TRAPS). Annals of the Rheumatic Diseases, 2015, 74, 852.3-853.	0.9	0
172	Follow-up and management of asymptomatic carriers of amyloidogenic Transthyretin (TTR) gene mutations. Journal of the Neurological Sciences, 2015, 357, e328-e329.	0.6	0
173	AB1305â€...EVALUATION OF SERUM LEVELS OF ASC FOR THE DIAGNOSIS AND MONITORING OF CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES (CAPS). , 2019, , .		0
174	OP0106â€...A NOVEL KNOCK-IN MOUSE MODEL OF CAPS THAT DEVELOPS AMYLOIDOSIS: THERAPEUTIC EFFICACY OF PROTON PUMP INHIBITORS. , 2019, , .		0
175	P3491 Circulating N terminal pro-brain natriuretic peptide as a marker of cardiac dysfunction in AL amyloidosis. European Heart Journal, 2003, 24, 678.	2.2	0
176	Thalidomide plus Intermediate-Dose Dexamethasone in Refractory/Relapsed Al Patients. , 2004, , 115-117.		0
177	Early Harvest Followed by Melphalan-Dexamethasone and Second-Line Autologous Stem Cell Transplantation in AL Amyloidosis.. Blood, 2006, 108, 5449-5449.	1.4	0
178	Prognostic Relevance of Serum N-Terminal Pronatriuretic Peptide Type B and Plasma Bnp in Patients with Al Amyloidosis in Dialysis. , 2007, , 273-274.		0
179	Early Harvest Followed by Melphalan-Dexamethasone and second-Line Autologous Stem Cell Transplantation in Al. , 2007, , 390-392.		0
180	Prolonged Follow-up Study of Al Patients Ineligible for Stem Cell Transplantation Treated with Oral Melphalan and Dexamethasone. , 2007, , 282-282.		0

#	Article	IF	Citations
181	Salvage Therapy with Lenalidomide and Dexamethasone (LDex) In Patients with Advanced AL Amyloidosis Refractory to Both Melphalan and Bortezomib. Blood, 2010, 116, 3062-3062.	1.4	0
182	AA amyloidosis without systemic inflammation: when clinical evidence validates predictions of experimental medicine. Kidney International, 2022, 101, 219-221.	5.2	0